COVID-19: Roche and Regeneron join forces
Roche and Regeneron have signed an manufacturing and distribution agreement on Regenerons Phase II therapeutic antibody for the treatment of COVID-19.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1120 entries already.
Entries by Thomas Gabrielczyk
Aicuris to launch AiCubator to fight AMR
/in News/by Thomas GabrielczykAntinfectives specialist AiCuris GmbH will launch the AiCubator, a new way to collaborate in anti-infectives and support novel approaches, at the 4th AMR Conference.
AI predicts mutations underlying neurological diseases
/in News/by Thomas GabrielczykUsing data from more than 20,000 patients with neurological diseases, researchers have established an algorithm that predicts whether mutations in ion channels will cause disease.
F2G bags 50.8m financing to advance olorofim
/in News/by Thomas GabrielczykUK-Austrian fungal infection specialist F2G Ltd has secured a 50.8m (US $60.8m) financing from new and existing investors.
Evotec receives $8.4m CARB-X funding
/in News/by Thomas GabrielczykEvotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8.4m funding from CARB-X for co-development of a first-in-class antibiotic.
BioNTech and Fosun Pharma kick off Chinese COVID-19 trials
/in News/by Thomas GabrielczykBioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials.
Evotec partners with Secarna to develop LNA drugs
/in News/by Thomas GabrielczykEvotec SE has secured a strategic partnership with Secarna Pharmaceuticals GmbH to co-develop a LNA drug pipeline.
EC secures 300 million doses of COVID-19 vaccine
/in News/by Thomas GabrielczykThe European Commission has reserved 300 million doses from Sanofi SA/GSK plcs adjuvanted recombinant COVID-19 vaccine.
Roche’s IL-6 receptor blocker fails in Phase III
/in News/by Thomas GabrielczykRoche has reported the failure of its IL-6R antagonist tocilizumab in patients with COVID-19 putting the efficacy of IL-6 inhibition at question.
Enthera Pharmaceuticals Srl raises 28m in Series A financing
/in News/by Thomas GabrielczykItalian start-up Enthera Pharmaceuticals has raised 28m to advance restorative therapy for type 1 diabetes and inflammatory bowel disease.